Author Title [ Type(Asc)] Year
Filters: Author is Kersten, Marie José  [Clear All Filters]
Journal Article
Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SRonan, van Besien K, Wagner-Johnston ND, et al. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4(3):560-572.
Sonneveld P, Asselbergs E, Zweegman S, van der Holt B, Kersten MJosé, Vellenga E, van Marwijk-Kooy M, Broyl A, de Weerdt O, Lonergan S, et al. Phase 2 study of carfilzomib, thalidomide and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma. Blood. 2014.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021.
Brink M, Meeuwes FO, van der Poel MWM, Kersten MJosé, Wondergem M, Mutsaers PGNJ, Böhmer LH, Woei-A-Jin FJSherida, Visser O, Oostvogels R, et al. Impact of Etoposide and ASCT on Survival Among Patients <65 years With Stage II-IV PTCL; a Population-Based Cohort Study.. Blood. 2022.
Persoon S, Kersten MJosé, Buffart LM, Slagmolen GVander, Baars JW, Visser O, Manenschijn A, Nollet F, Chinapaw MJM. Health-related physical fitness in patients with multiple myeloma or lymphoma recently treated with autologous stem cell transplantation. J Sci Med Sport. 2016.
Mank APM, Schoonenberg C, Bleeker K, Heijmenberg S, de Heer K, van Oers MHJ, Kersten MJosé. Early discharge after high dose chemotherapy is safe and feasible: a prospective evaluation of 6 years of home care. Leuk Lymphoma. 2014:1-20.